Pharmalink AB Receives US Orphan Drug Designation for Nefecon® (PL-56)

Pharmalink AB closes deal with Grifols SA for the Acquisition of the Xepol® programme for the treatment of post-polio syndrome

Grifols agrees to acquire intellectual property for treatment of post-polio syndrome from Pharmalink AB